Navigation Links
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Date:9/5/2007

or two-stent implantation) significantly influenced MACCE outcomes. The freedom- from-MACCE rate for true bifurcations was 81.9 percent, compared to 78.1 percent for partial bifurcations (p=0.58). The one-stent implantation strategy produced a freedom-from-MACCE rate of 82.0 percent, compared to 79.3 percent for the two-stent strategy (p=0.60). Bifurcations are associated with increased case complexity.

In addition, the ARTS II Study investigators reported stent thrombosis rates for the CYPHER(R) Stent using the ARC definitions. The definite, definite/probable and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at three years were 3.3 percent, 5.3 percent and 6.4 percent, respectively. Stent thrombosis comparisons between the CYPHER(R) Stent and the bare metal stent were not possible as ARC stent thrombosis rates for the ARTS I Study were not available and the ARTS I Study did not track stent thrombosis rates beyond 30 days. The protocol stent thrombosis rate for the bare metal stent arm was 2.8 percent at 30 days of follow-up, while the ARC definite definite/probable and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at 30 days were 1.0 percent, 1.5 percent and 1.5 percent, respectively.

In lieu of ARC stent thrombosis rates for the bare metal stent, the clinical investigators pointed out that the rate of myocardial infarction for the CYPHER(R) Stent was significantly lower than that of the bare-metal stent (3.6 percent for the CYPHER(R) Stent versus 6.8 percent for the bare metal stent, p=0.014). In addition, the mortality rate for the CYPHER(R) Stent was numerically lower than that of the bare metal stent, although this difference did not reach statistical significance (3.0 percent for the CYPHER(R) Stent versus 4.0 percent for the bare metal stent, p=0.33). These rates favored the CYPHER(R) Stent in spite of the fact that the patients treated with the drug- eluting stent were significantly more co
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  Legendary actor and director ... new PBAFacts campaign designed to educate and encourage patients ... about Pseudobulbar Affect (PBA) and to speak with their ... actor has the ability to cry and laugh on ... control experienced by people living with PBA episodes. ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/2/2015)... TX (PRWEB) May 02, 2015 ... skin laxity issues of the face, neck and ... new concept with real potential for the success ... by the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s ... FACOG, FACS, ACGE, concluded that ThermiGyn’s temperature controlled ...
(Date:5/2/2015)... the success that Veatch Dental Consulting has had over the ... Alex Shields to the team. With Neida and Alex on ... experience working with dentists to ensure their success. , Neida ... She was certified as dental assistant from Texas State ... showing the importance of oral hygiene to patients, Neida was ...
(Date:5/1/2015)... Islands, BWI (PRWEB) May 02, 2015 ... It is http://www.thevenetiangracebay.com , and it is ... incorporates the stunning white and attractive turquoise hues of ... of Google, sixty seven percent of leisure travelers used ... showed that smartphones were used in the planning and ...
(Date:5/1/2015)... May 01, 2015 Jusuru International has ... the successful repositioning of its flagship nutritional supplement, Liquid ... with a new name, new logo, new packaging, new ... Awards are designed to identify and promote programs that ... , “DSA congratulates Jusuru International for their outstanding ...
(Date:5/1/2015)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies in ... to the United States Government Accountability Office (GAO) for ... in Medicare. The report, “ Potential Uses of Electronically ... to the public on Apr. 24, 2015 and examines ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... out the best place to live by eavesdropping on ... birds a communication and behavioral trait so strong ... in places they otherwise would have avoided. , This ... had previously been understood, researchers say, and that these ...
... Ill., June 18 Custom print and ... a division,of MediMedia USA, has announced a ... clients the industry-leading, innovative online behavior,change programs ... health information and,engagement solutions., HealthMedia,s online ...
... Fla., June 18 eDiets.com,Inc. (Nasdaq: DIET ... diet,fitness and healthy lifestyle solutions to everyone, has ... effective immediately.,Bringing over 8 years of senior business ... CIO and VP of IT at Sheridan Healthcare ...
... (Pink Sheets: CGCP), a leading developer of ... upcoming scientific,presentation that describes the use of ... (PRP)., The presentation titled "Intramyocardial Injection ... Revascularization" will,be presented by Kurt E. Wehberg, ...
... in the event of a disease pandemic and will be forced ... of sick and dying. In order to protect themselves and allow ... be fully prepared by getting available vaccines now. , But how ... at a time when no threat is imminent, and they are ...
... The American Medical,Association (AMA) announced today the re-election ... surgeon, to his second consecutive,term as vice speaker ... position, Dr.,Gurman will assist in presiding over the ... "I look forward to continuing to encourage physicians ...
Cached Medicine News:Health News:Birds communicate reproductive success in song 2Health News:Birds communicate reproductive success in song 3Health News:StayWell Custom Communications Announces Strategic Alliance With HealthMedia 2Health News:StayWell Custom Communications Announces Strategic Alliance With HealthMedia 3Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 2Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 3Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 4Health News:Effective health messages may yield vaccine compliance among ER workers 2
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: